If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Benign prostatic hyperplasia (BPH) is a common condition in aging men that is characterized bynonmalignant enlargement of the prostate gland, and is frequently accompanied by urinary obstruction, andlower urinary tract symptoms (LUST). Currently pharmacotherapy of BPH is based on two classes of drugs: α1-adrenoceptor (α1-AR) antagonists and α5-reductase inhibitors. It has been shown that α1-AR antagonistsreduce symptom scores and increase peak urinary flow rates in BPH. Of particular importance for BPH therapyare uroselective α1-AR antagonists for which the hypotensive related side-effect caused by α1-AR blockade isreduced. α5-Reductase inhibitors reduce prostate volume and symptom scores, while increasing peak urinaryflow rates. This review describes new α1-AR antagonists and 5α-reductase inhibitors in the treatment of BPH.The new α1-AR antagonists represent various structures such as quinazolines, phenylethylamines, piperidines,and arylpiperazines.5α-Reductase inhibitors are classified into two groups: steroidal and non-steroidal. Thenewer non-steroidal inhibitors include derivatives of benzo[c]quinolizinones, benzo[f]quinolonones,piperidones and carboxylic acids. Besides the development of new compounds belonging to the abovementioned groups, new agents for BPH treatment are sought among combined 5α-reductase/α1-AR inhibitors,endothelins, androgen receptors antagonists, growth factors, estrogens and phosphodiesterase isoenzymes aswell as several phytomedicines, used for prevention and treatment of prostate disorders. These new agents canbe used for the design of future targets and development of new drugs in the treatment of BPH. The discoveryof a number of active leads may also ultimately help in developing new safe and effective drugs.

Keywords: 5α-reductase inhibitors; Benign prostatic hyperplasia; a1α-adrenoceptor antagonists

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986706779010315

Affiliations: Department of Physicochemical Drug Analysis, Jagiellonian University Medical College,Medyczna 9 str., 30-688 Krakow, Poland.

Publication date: December 1, 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more